Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31507012 | 0.78 | CHRM4 (0.42) | CHRM4CHRM5CHRM1CHRM3CHRNB4 | |
| SCHEMBL6008921 | 0.78 | CHRM4 (0.42) | CHRM4CHRM5CHRM1CHRM3CHRNB4 | |
| SCHEMBL18824669 | 0.78 | PIK3CA (0.38) | GAAL3MBTL1RAB9AKMT2APIK3CA | |
| SCHEMBL19054141 | 0.78 | NOS2 (0.40) | GAAL3MBTL1RAB9APIK3CANOS1 | |
| SCHEMBL18645383 | 0.78 | CHRM4 (0.42) | CHRM4CHRM5CHRM1CHRM3CHRNB4 | |
| SCHEMBL4700942 | 0.77 | TDP1 (0.46) | CHRM4CHRM5CHRM1CHRM3CHRNB4 | |
| SCHEMBL14871075 | 0.77 | HTR3A (0.46) | HTR3AKCNH2GAAL3MBTL1RAB9A | |
| SCHEMBL23097041 | 0.75 | GAA (0.35) | GAAL3MBTL1PIK3CA | |
| SCHEMBL21604478 | 0.75 | CHRM4 (0.40) | CHRM4CHRM5CHRM1CHRM3CHRNB4 | |
| SCHEMBL12910354 | 0.75 | NPC1 (0.47) | CHRM4CHRM5CHRM1CHRM3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11818932-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-14 | — | — | US | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-11706973-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-11696496-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11696499-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11696499-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11696491-B2 | Organometallic compound, organic light-emitting device including the same and apparatus including the organometallic compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11678498-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-13 | — | — | US | disclosed |
| US-11678498-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-13 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2012074126-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | WO | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| WO-2011136385-A1 | BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-03 | — | — | WO | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | CHRM4 4614/4885CHRM5 4752/4885CHRM1 4480/4885 |
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CHRM4 3106/4885CHRM5 1630/4885CHRM1 2336/4885 |
| US-11706973-B2 | Condensed cyclic compound and organic light-emitting device including the same | C1S, CCNT1, C9 | CHRM4 64/4885CHRM5 94/4885CHRM1 4/4885 |
| US-20110263562-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CHRM4 2442/4885CHRM5 1287/4885CHRM1 1615/4885 |
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | CHRM4 3937/4885CHRM5 3987/4885CHRM1 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.